PHYSICIANS' HEALTH STUDY A randomized, double-blind, placebo controlled trial designed to test the effects of low-dose aspirin and beta- carotene in the.

Slides:



Advertisements
Similar presentations
The results of the Study of Heart and Renal Protection (SHARP)
Advertisements

The Risk Concept in health care Definition of a risk factor  a disease precursor associated with a higher than average morbidity or mortality rate. John.
The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
OPPORTUNITIES FOR RESEARCH IN PRIMARY CARE Jen Dumbleton Clinical Trial Manager University of Nottingham
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.
Body Mass Index, Weight Change and Death in an Older Hypertensive Population: The SHEP Study Grant W Somes Stephen B Kritchevsky Marco Pahor Ronald I Shorr.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
CARDIOVASCULAR DISEASE WHERE ARE WE GOING IN THE NEW MILLENNIUM.
A Randomized Trial of a Multivitamin in the Prevention of Cardiovascular Disease in Men: The Physicians’ Health Study II HD Sesso, WC Christen, V Bubes,
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Improving the Quality of Physical Health Checks
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Journal Club Hallie Lee PharmD Candidate 2013 Mercer University COPHS PHA 618 Geriatrics-Continuous Care Multivitamins in the Prevention of Cardiovascular.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Rationale, Study Design & Study Population
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
WHI CT Sample Size, Outcomes, Follow-up Women, aged Total CT = 68,133 Diet Modification (DM) Trial Primary Outcomes: Breast & Colorectal Cancer Secondary.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2015.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
1 Joint NDAC/EMDAC Meeting January 13, 2005 Mevacor TM Daily 20 mg Tablets Rx-to-OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products.
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
Dr. Nadira Mehriban. INTRODUCTION Diabetic retinopathy (DR) is one of the major micro vascular complications of diabetes and most significant cause of.
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (HOPE-3 trial) R4. 박은지 / PF. 정혜문 Salim Yusuf, M.B., B.S., D.Phil.,
Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.
Randomised vitamin E supplementation and risk of chronic lung disease in the Women’s Health Study Anne H Agler, Tobias Kurth, J Michael Gaziano, Julie.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Date of download: 6/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Homocysteine-Lowering With Folic Acid.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
Angela Aziz Donnelly April 5, 2016
Title slide.
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Copyright © 2007 American Medical Association. All rights reserved.
The Anglo Scandinavian Cardiac Outcomes Trial
ELIGIBILITY: MRC/BHF Heart Protection Study
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.
Cardiovascular Disease (CVD) in Texas
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
The Hypertension in the Very Elderly Trial (HYVET)
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
The prevalence of Recurrent Stroke and TIA and the related factors
Presentation transcript:

PHYSICIANS' HEALTH STUDY A randomized, double-blind, placebo controlled trial designed to test the effects of low-dose aspirin and beta- carotene in the primary prevention of CVD and cancer among 22,071 US male physicians, aged 40 to 84 at baseline in Baseline blood specimens were collected and frozen for later analyses from 14,916 participants. Using a 2x2 factorial design: 325 mg of aspirin (Bufferin, supplied by Bristol-Myers Products on alternate days) 50 mg of beta-carotene (Lurotin, supplied by BASF AG on alternate days)

PHYSICIANS' HEALTH STUDY Randomized aspirin component terminated early, on 1/25/88 Randomized beta carotene component ended, as scheduled, on 12/21/95 After an average duration of beta carotene treatment and follow-up of 12 years:  Fewer than 1% of participants were lost to morbidity and mortality follow-up  Compliance with pill-taking was > 80%

Rationale for Choosing Physicians Ability to give true informed consent Knowledge of possible side effects Accuracy and completeness of information Ease of follow-up Opportunity to conduct trial by mail

Personal history of Myocardial infarction Stroke or TIA Cancer (except nonmelanoma skin cancer) Current liver or kidney disease Peptic ulcer or gout Contraindication to aspirin use Current use of aspirin or other drugs affecting platelet function Current use of vitamin A or beta-carotene supplement Exclusion Criteria PHYSICIANS' HEALTH STUDY

Total cancer Prostate cancer Cardiovascular disease Eye disease ä Cataract ä Macular degeneration Primary Endpoints

PHYSICIANS’ HEALTH STUDY 261,248 U.S. male MD’s, aged ,528 respondents to questionnaires 59,285 willing to participate Population Hierarchy

33,223 willing and eligible MDs enrolled in run-in (18 weeks on active aspirin and beta-carotene placebo) 22,071 randomized PHYSICIANS’ HEALTH STUDY Run-in Phase

Randomization Scheme PHYSICIANS' HEALTH STUDY 22,071 Randomized 11,037 Aspirin 11,037 Aspirin placebo 5,517 Beta-carotene 5,520 Beta-carotene placebo 5,519 Beta-carotene 5,515 Beta-carotene placebo

Baseline Characteristics AssignmentASA + BCASA + PLPL + BCPL + PL (n = 5,517)(n = 5,520)(n = 5,519)(n = 5,515) Demographic Mean age (years)53.2± ± ± ±9.5 Geographic region Northeast Midwest South or Southwest Mountain or Far West Other PHYSICIANS' HEALTH STUDY I

Baseline Characteristics AssignmentASA + BCASA + PLPL + BCPL + PL Medical history Reported hypertension Mean systolic BP 126.0± ± ± ±11.7 Mean diastolic BP 78.8± ± ± ±7.5 High cholesterol Mean cholesterol mg/dl)211.7± ± ± ±44.8 Diabetes mellitus Mean BMI 24.9± ± ± ±3.0 Overweight History of angina pectoris Parental history of Ml PHYSICIANS' HEALTH STUDY I

Baseline Characteristics AssignmentASA + BCASA + PLPL + BCPL + PL Health habits Cigarette smoking Never Past only Current Mean cigarettes/day21.7± ± ± ±13.5 <15 (of current smokers) (of current smokers) (of current smokers) Current cigar smoking Current pipe smoking PHYSICIANS' HEALTH STUDY I

Baseline Characteristics AssignmentASA + BCASA + PLPL + BCPL + PL Health habits Alcohol use Mean drinks/week3.5±3.23.5±3.23.5±3.23.5±3.3 Daily Rarely or never Exercise frequency Mean times/month10.2±8.59.8± ± ±8.6 Rarely or never PHYSICIANS' HEALTH STUDY I